Depression: The Disorder And The Burden
Today, depression is a global health burden and continues to rise with each passing day. As per the WHO, globally, more than 264 million people of all ages suffer from depression. Besides physical and mental illness, it is associated with a high suicides risk or suicidal behaviour. It is observed that several social, psychological, environmental and biological factors lead to the development of depression.
Major Depressive Disorder (MDD), Manic depression (bipolar disorder), Postpartum Depression, Persistent Depressive Disorder (PDD), Premenstrual Dysphoric Disorder (PMDD), Seasonal Affective Disorder (SAD), Atypical Depression are the most common depression that affects the significant proportion of population worldwide.
To address the rising cases of Depression and to provide an effective therapeutic option, companies such as Axsome Therapeutics, Inc., Minerva Neurosciences, Relmada Therapeutics, Inc, Intra-Cellular Therapies, Sage Therapeutics, Celon Pharma S.A. Otsuka Pharmaceutical Companies (U.S.), NeuroRx, Inc., among several others, are diligently involved in developing therapies for Depression. In the coming years, the launch of innovative treatments, increased investments in R&D, and rising awareness are expected to improve the situation for the people affected with depression and their families.
For more details, visit: Depression: The Disorder And The Burden